Parker Waichman LLP

Singulair Safety Review Ongoing

Federal regulators said today that they are continuing a probe into the psychiatric side effects of Singulair and similar asthma drugs.  The Food & Drug Administration (FDA) began looking into the drugs’ potential psychiatric side effects last March, after it received several reports of suicidal behavior in patients taking Singulair. Singulair, made by Merck & […]

Federal regulators said today that they are continuing a probe into the psychiatric side effects of <"https://www.yourlawyer.com/practice_areas/defective_drugs">Singulair and similar asthma drugs.  The Food & Drug Administration (FDA) began looking into the drugs’ potential psychiatric side effects last March, after it received several reports of suicidal behavior in patients taking Singulair.

Singulair, made by Merck & Co., is one of a class of drugs called leukotriene receptor antagonists. Singulair was approved to treat asthma and the symptoms of allergic seasonal allergies and to prevent exercise-induced asthma. Side effects of Singulair include gastrointestinal disturbances, hypersensitivity reactions, sleep disorders and increased bleeding tendency. Other leukotriene modifying medications include Accolate, which is also a leukotriene receptor antagonist and Zyflo and Zyflo CR, which are leukotriene synthesis inhibitors.

At the time of its March 2008 Early Communication, the FDA said it was working with Merck to further evaluate a possible link between the use of Singulair and behavior/mood changes, suicidality and suicide. The FDA  requested that Merck evaluate Singulair study data for more information about suicidality and suicide.  The FDA asked Merck, as well as  AstraZeneca PLC, the maker of Accolate, and Cornerstone Therapeutics Inc., the maker of Zyflo, to submit post-marketing reports and other information for the review. The FDA said then that it anticipated that its safety review would take approximately 9 months.

Today, the <"https://www.yourlawyer.com/practice_areas/defective_drugs">FDA said Merck submitted results from 41 placebo-controlled clinical trials in which 9,929 patients were treated with Singulair and 7,780 were treated with a placebo. One adult patient out of 9,929 patients treated with Singulair had suicidal thoughts and there were no completed suicides. AstraZeneca submitted results from 45 placebo-controlled clinical trials in which 7,540 patients were treated with Accolate and 4,659 were treated with a placebo. The agency said one patient in the placebo group attempted suicide and another thought about suicide. No patients on Accolate reported any suicidal behavior. The FDA said information submitted by Cornerstone showed no suicidal behavior in either the Zyflo groups or placebo groups.

The FDA said that it appears the data submitted by the companies would suggest the products aren’t associated with suicide or suicidal behavior, however it noted that the trials weren’t designed to look at such behavior.  The agency said it was continuing to review clinical trial data to assess other neuropsychiatric events such as mood and behavioral adverse events related to the drugs.

According to the FDA, most of the reports of other neuropsychiatric events are associated with Singulair. The agency said the clinical details of some Singulair reports are consistent with a drug-induced effect.  Because of the paucity of reports involving Accolate and Zyflo, assessment of a drug–induced effect with these is limited, the FDA said. The agency is advising patients and doctors to monitor for the possibility of neuropsychiatric events associated with these drugs.

In the FDA Early Communication issued today, the agency said the safety review “may take months to complete.”

What Our Clients Say About Us
We have worked with thousands of clients and we appreciate them and their positive reviews. Here are just a few recent client reviews...
5 Star Reviews 150
I had a wonderful experience with ms burgess an will deal with this company again.
Butter Fly
a year ago
5 Star Reviews 150
They got the job done!
Stephanie Fede
4 years ago
5 Star Reviews 150
Today i just received my acceptance letter from the W.T.C and VCF just wanna say the excellent work of your employee trisha and christina morace did a fairy good job I would love them to represent me anytime Under any situation. A extra special thank you for that for those great employees.
andre facey
7 months ago

Why Choose Us to Help You?

We Take Care of Everything
Your situation is stressful enough: Let us take on the deadlines, paperwork, investigation, and litigation. We'll handle every detail so you don't have to worry.
No Recovery = No Legal Fees
We work on a contingency-fee basis, meaning that we only get paid from a portion of your settlement or jury award. If you don't get compensation, you owe us nothing.
Decades of Experience
Your situation is stressful enough: Let us take on the deadlines, paperwork, investigation, and litigation. We'll handle every detail so you don't have to worry.
Respected by Our Peers
Judges, insurance adjusters, and fellow attorneys all speak highly of our skills, and we've earned numerous accolades, including a flawless rating from AVVO.
We Have Many Locations To Serve You
We have the experience and the skilled litigators to win your case. Contact us and speak with a real attorney who can help you.
Long Island – Nassau
Parker Waichman LLP
6 Harbor Park Drive
Port Washington, NY 11050
Long Island – Suffolk
Parker Waichman LLP
201 Old Country Road – Suite 145
Melville, NY 11747
New York
Parker Waichman LLP
59 Maiden Lane, 6th Floor
New York, NY 10038
Queens
Parker Waichman LLP
118-35 Queens Boulevard, Suite 400
Forest Hills, NY 11375
Brooklyn
Parker Waichman LLP
300 Cadman Plaza West
One Pierrepont Plaza, 12th Floor
Brooklyn, NY 11201
New Jersey
Parker Waichman LLP
80 Main Street, Suite 265
West Orange, NJ 07052
Florida
Parker Waichman LLP
27299 Riverview Center Boulevard
Suite 108
Bonita Springs, FL 34134
Nationwide Service
Parker Waichman LLP
59 Maiden Lane, 6th Floor
New York, NY 10038